Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Longvida is a patented curcumin formulation that uses Solid Lipid Curcumin Particle (SLCP) technology to enhance bioavailability up to 285 times compared to standard curcumin. It works by inhibiting COX-2 enzymes and reducing amyloid plaque formation for joint and cognitive health benefits.
Reported Benefits (Provisional)
Origin & History
Longvida is a specialized curcumin formulation using Solid Lipid Curcumin Particle (SLCP) technology to enhance absorption and bioavailability.
Research Narrative (Provisional)
Research, including RCTs, supports Longvida's efficacy in improving cognitive function and reducing inflammation due to its enhanced bioavailability.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Longvida (Curcumin SLCP) is a specialized patented curcumin delivery system, not a whole food, so macronutrient content is negligible. Primary bioactive compound: curcumin (diferuloylmethane) at approximately 20-22% curcumin content by weight within the SLCP (Solid Lipid Curcumin Particle) matrix. A typical 400mg Longvida dose delivers approximately 80-88mg of free curcumin. The SLCP formulation encapsulates curcumin in a phospholipid and food-grade lipid matrix (including phosphatidylcholine and other GRAS lipid excipients), which protects curcumin from first-pass metabolism and gastric degradation. Minor curcuminoids present include demethoxycurcumin (~15-20% of curcuminoid fraction) and bisdemethoxycurcumin (~3-5% of curcuminoid fraction). Bioavailability is the defining characteristic: Longvida achieves approximately 65-fold greater bioavailability compared to standard unformulated curcumin powder, with plasma free curcumin concentrations reaching measurable levels (unlike standard curcumin which is largely undetectable in plasma). Longvida preferentially delivers free (unconjugated) curcumin to tissues including crossing the blood-brain barrier, a critical distinction from other enhanced curcumin formulations. Negligible protein, carbohydrate, and fat macronutrient contribution at standard doses. No significant vitamins or minerals present.
Reported Mechanism (Provisional)
Longvida's curcumin crosses the blood-brain barrier and inhibits cyclooxygenase-2 (COX-2) enzymes, reducing inflammatory prostaglandin production. The SLCP formulation encapsulates curcumin in lipid particles, bypassing first-pass metabolism and enabling sustained plasma levels. It also modulates NF-κB signaling pathways and reduces beta-amyloid aggregation in neural tissues.
Clinical Narrative (Provisional)
Human studies demonstrate Longvida's superior bioavailability with 285-fold higher free curcumin levels compared to standard extracts. A 12-week randomized controlled trial (n=60) showed 30% improvement in cognitive performance measures in healthy adults. Additional studies report significant reductions in inflammatory markers like C-reactive protein within 4-6 weeks. However, most cognitive studies are small-scale and require larger replication trials.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.